Navigation Links
Gen-Probe to Webcast Two Upcoming Investor Presentations
Date:5/8/2008

ees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. For information about risks and uncertainties we face and a discussion of our financial statements and footnotes, see documents we have filed with the SEC, including the Form 10-K for the year ended December 31, 2007, and all subsequent periodic filings made with the SEC. We assume no obligation and expressly disclaim any duty to update any forward-looking statement to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events.

Contact:

Paula Izidoro

Investor Relations

858-410-8904


'/>"/>
SOURCE Gen-Probe Incorporated
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Gen-Probe Announces Webcast of First Quarter 2008 Earnings Conference Call
2. Gen-Probe to Webcast Presentation at Leerink Swann Molecular Diagnostics Conference
3. Gen-Probe to Webcast Presentation at Deutsche Bank Small- and Mid-Cap Growth Conference
4. Gen-Probe to Webcast Presentation at 26th Annual JPMorgan Healthcare Conference
5. Gen-Probe to Webcast Presentation at NASDAQ 20th Investor Program
6. Jorgine Ellerbrock Joins Gen-Probe as Senior Vice President, Operations
7. 3M, Gen-Probe to Discontinue Molecular Food Testing Collaboration
8. Webcast Alert: Medial Saude S/A Announces First Quarter 2008 Earnings Conference Call Webcast
9. ENDO 08 preliminary news conference and webcast schedule
10. Aflac Incorporated to Webcast 2008 Financial Analysts Briefing
11. Webcast Advisory - The Westaim Corporation Webcast of Annual Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2008)...h Annual Physician On-Call Pay .../ -- Sullivan, Cotter and Associates, Inc.,has pub...ll pay rates and,practices, the 2008 Physician On-...ta from 132 healthcare organizations nationwide, o...paid for 33 physician specialty areas along,with d...
(Date:7/25/2008)...lusivity Begins -, CORONA, Calif., July 25 /PRNew...NYSE: WPI ), a leading specialty pharmaceutical,c...mmenced commercial,shipment of its Omeprazole Dela...gth from its Davie, Florida manufacturing facility...ays of marketing exclusivity for being the,first t...
(Date:7/25/2008)...ert J. Reilly, Joins Aethon Team, PITTSBURGH, Jul...on.com ), the leading developer of mobile robotics...ced that Robert J. Reilly has,joined the company a...., Reilly, who was most recently Vice President -...alty Pharmacy Division, brings more than 30,years ...
(Date:7/25/2008)...ekta Family of Companies will,showcase their uniqu...merican Association of Physicists in Medicine (AAP...ces of Elekta, IMPAC and CMS are delivering,cuttin...utions that,streamline the treatment process to cr...enhance clinician efficiency., "Our recent acquis...
Breaking Medicine News(10 mins):Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 2Health News:Hospital Expenditures for Physician On-Call Pay Rates Nearly Double 3Health News:Watson Launches Omeprazole Delayed-Release Capsules, 40MG 2Health News:Aethon, Inc. Names New Chief Financial Officer 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 2Health News:Elekta Family of Companies to Highlight Cancer Treatment Solutions at 2008 AAPM Annual Meeting 3
...ther the reasons for swallowing the mobile phone b...or she purposely swallowed the mobile phone. // Th... in which it is said that the young lady purposely...th her boy friend in which she did not want to giv...
... two Israeli ophthalmologists Professor Michael Be...schleger Eye Institute at the Sheba Medical Centre...; They said that they have co-related all the prev...me out with strong evidences that obesity is the c...
...ave reported to have dead chicken and the cause th...ad chickens were tested and they showed positive r...placed an eastern town under scrutiny and have bee... of disease to other birds. The virus was first d...
...e polio eradication programme, initiated before 17...ent regions of the world. The programme was aimed ...of 2005. // The initiative, started in 1988, had a...adline has been set, and success may depend, in pa...
Other Medicine News:Health News:Increased Risk Of Losing Sight In Obese People. 2Health News:The Slow And Steady Race To Eradicate Polio Offers Hope 2
(Date:7/24/2008)...y 24 /- Ortho-McNeil Neurologics, a,d...nc., announced today,that the U.S. Food and Drug A...ity for TOPAMAX(R) (topiramate), based on studies ...FDA to investigate the use of TOPAMAX,in pediatric...eizures., In addition to granting pediatric exclu...
(Date:7/24/2008)..., July 24 /- Alexza,Pharmac...at it has initiated,its second Phase 3 clinical tr...an inhalation product candidate being developed fo...h schizophrenia or bipolar disorder.,Alexza believ...cokinetic,(PK) properties resulting from inhaled l...
(Date:7/24/2008)...PRNewswire-USNewswire/ -- Headlines claiming "soy,...story. The small scale,preliminary study that Dr....ction, is based on recollected intake of soyfoods ...is study is confounded by many,issues, thus I feel...,caution," warned Dr. Tammy Hedlund, a researcher ...
(Date:7/24/2008)...eter designed to take body temperature, for home,a...e-FirstCall/ --- Kidz-Med, Inc.,(subsidiary of Ame...,United States distributor of the Thermofocus(R) ...unce the results of a clinical study,conducted by ...Milan, in,Milan, Italy, which proves that the Ther...
Breaking Medicine Technology:FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months 2FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months 3Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 2Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 3Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 4Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 5Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 6Soyfoods Do Not Impact Sperm Count 2Pediatric Study Finds 21st Century Non-Contact Thermometer as Accurate as Conventional Thermometers 2The Stay Strong Foundation Launches National Healing Starts With US Campaign With Celebrity Guests Denzel Washington Ruby Dee MoNique Terry McMilla 14367 1The Stay Strong Foundation Launches National Healing Starts With US Campaign With Celebrity Guests Denzel Washington Ruby Dee MoNique Terry McMilla 14367 2The Stay Strong Foundation Launches National Healing Starts With US Campaign With Celebrity Guests Denzel Washington Ruby Dee MoNique Terry McMilla 14367 330 National Organizations Issue Call to Action for Congress to Fully Fund Falls Prevention Programming in CDC Budget 14364 130 National Organizations Issue Call to Action for Congress to Fully Fund Falls Prevention Programming in CDC Budget 14364 230 National Organizations Issue Call to Action for Congress to Fully Fund Falls Prevention Programming in CDC Budget 14364 3JCI online early table of contents 3A March 13 2008 14362 1JCI online early table of contents 3A March 13 2008 14362 2JCI online early table of contents 3A March 13 2008 14362 3JCI online early table of contents 3A March 13 2008 14362 4JCI online early table of contents 3A March 13 2008 14362 5JCI online early table of contents 3A March 13 2008 14362 6JCI online early table of contents 3A March 13 2008 14362 7Lung Cancer Alliance Commends Leadership of MA State Senate 14360 1Lung Cancer Alliance Commends Leadership of MA State Senate 14360 2
...DGEWATER, N.J., July 05, 2007 /PRNewswire/ -- Resu...trolled, open-label, Phase,3 study showed that 77 ...ults taking PREZISTA(TM) (darunavir) 600 mg tablet...plus an optimized,background regimen (OBR) of anti...ad of <400 copies/mL at week 48, compared to 68,pe...
...rst prospective biomarker trial in non-small cell ...ire-FirstCall/ -- Response,Genetics, Inc. today an...ished in the July 1 issue of the Journal of Clinic...omarker,Excision-Repair Cross-Complementing 1 (ERC...ell lung cancer (NSCLC) predicts for,sensitivity t...
Other Medicine Technology:New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 2New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 3New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 4New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 5New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 6New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 7New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 8Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 2Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 3Response Genetics Announces Publication of a Phase III Clinical,Trial Demonstrating That Low Levels of ERCC-1 Help to Predict,Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer 4
No Scalpel Vasectomy Ring Clamp, 5 1/2" (14cm), gold finger rings
Non-Cantilevered, "Teardrop" Ringed Forceps. ("fixation clamp") For vasectomy and other procedures. Ring ovoid approximately 6.0 mm in diameter.
Li Brand™ Ringed Forceps. ("fixation clamp") For NSV and other procedures. Ring diameter approximately 3.5 mm. Manufactured exclusively for AMI to exacting specifications by a German company.
...dule is an inconspicuous, lightweight, battery-ope...need to hear body functions amplified., ,The modu... integrated on/off switch, a tone switch, a stetho... The tone switch will allow the user to select bet...
Medicine Products: